国: イギリス
言語: 英語
ソース: MHRA (Medicines & Healthcare Products Regulatory Agency)
Chlortalidone
Ennogen Healthcare Ltd
C03BA04
Chlortalidone
50mg
Oral tablet
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 02020100
Your medicine is known by the above name but will be referred to Chlortalidone throughout this leaflet. READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. • This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours. • If any of the side effects get serious, or if you notice any side effects not listed in this leaflet please tell your doctor or pharmacist. The information in this leaflet has been divided into the following sections: 1. WHAT CHLORTALIDONE IS AND WHAT IT IS TAKEN FOR 2. CHECK BEFORE YOU TAKE CHLORTALIDONE 3. HOW TO TAKE CHLORTALIDONE 4. POSSIBLE SIDE EFFECTS 5. HOW TO STORE CHLORTALIDONE 6. FURTHER INFORMATION 1. WHAT CHLORTALIDONE IS AND WHAT IT IS TAKEN FOR Chlortalidone belongs to a group of medicines called thiazide diuretics. Thiazide diuretics help to reduce the amount of water in your body. They do this by increasing the amount of water that you pass as urine. They are sometimes called ‘water tablets’. Chlortalidone is used to: • treat high blood pressure (hypertension) • treat heart failure • help reduce the fluid retention that occurs with some kidney or liver diseases • treat diabetes insipidus (a condition in which an individual produces large amounts of dilute urine and is constantly thirsty). 2. CHECK BEFORE YOU TAKE CHLORTALIDONE DO NOT TAKE CHLORTALIDONE: • if you are allergic (hypersensitive) to chlortalidone, sulphonamides such as sulfamethoxazole or any of the ingredients of Chlortalidone (see Section 6 Further information) • if you are not passing any urine at all • if you have severe kidney or liver problems • if you have low blood levels of potassium which can cause muscle weakness, muscle twitching or abnormal heartbeat • if you have low blood levels of sodium which can cause tiredness, confusion, muscle twitching, fits or coma • i 完全なドキュメントを読む
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Hygroton Tablets 50mg Chlortalidone 50mg Tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Chlortalidone Ph.Eur 50mg. 3. PHARMACEUTICAL FORM Pale yellow, round, flat tablets with bevelled edges, impressed Geigy on one side with a breakline, and the letters Z/A on the other side. 4. CLINICAL PARTICULARS 4.1. THERAPEUTIC INDICATIONS Treatment of arterial hypertension, essential or nephrogenic or isolated systolic. Treatment of stable, chronic heart failure of mild to moderate degree (New York Heart Association, NYHA: functional class II or III). _Oedema of specific origin _ • Ascites due to cirrhosis of the liver in stable patients under close control. • Oedema due to nephrotic syndrome. Diabetes Insipidus. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION The dosage of Hygroton/Chlortalidone should be individually titrated to give the lowest effective dose; this is particularly important in the elderly. Hygroton/Chlortalidone should be taken orally, preferably as a single daily dose at breakfast time. _Adults: _ _Hypertension _ The recommended starting dose is 25mg/day. This is sufficient to produce the maximum hypotensive effect in most patients. If the decrease in blood pressure proves inadequate with 25mg/day, then the dose can be increased to 50mg/day. If a further reduction in blood pressure is required, additional hypertensive therapy may be added to the dosage regime. _Stable, chronic heart failure (NYHA: functional class II /III): _ _ _ The recommended starting dose is 25 to 50mg/day, in severe cases it may be increased up to 100 to 200mg/day. The usual maintenance dose is the lowest effective dose, eg 25 to 50mg/day either daily or every other day. If the response proves inadequate, digitalis or an ACE inhibitor, or both, may be added. (See Section 4.4 “Special warnings and precautions for use”). _Oedema of specific origin (see Section 4.1 “Therapeutic indications”) _ The lowest effective dose is to be identified by titration and adm 完全なドキュメントを読む